Asset Details
Do you wish to reserve the book?
Outcomes of Cytologically Indeterminate Thyroid Nodules Managed With Genomic Sequencing Classifier
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Outcomes of Cytologically Indeterminate Thyroid Nodules Managed With Genomic Sequencing Classifier
Do you wish to request the book?
Outcomes of Cytologically Indeterminate Thyroid Nodules Managed With Genomic Sequencing Classifier
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Outcomes of Cytologically Indeterminate Thyroid Nodules Managed With Genomic Sequencing Classifier
2024
Overview
Abstract
Context
Molecular testing can refine the risk of malignancy in thyroid nodules with indeterminate cytology to decrease unnecessary diagnostic surgery.
Objective
This study was performed to evaluate the outcomes of cytologically indeterminate thyroid nodules managed with Afirma genomic sequencing classifier (GSC) testing.
Methods
Adult patients who underwent a biopsy at 3 major academic centers between July 2017 and June 2021 with Bethesda III or IV cytology were included. All patients had surgery or minimum follow-up of 1 year ultrasound surveillance. The primary outcomes were the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of GSC in Bethesda III and IV nodules.
Results
The median nodule size of the 834 indeterminate nodules was 2.1 cm and the median follow-up was 23 months. GSC sensitivity, specificity, PPV, and NPV across all institutions were 95%, 81%, 50%, and 99% for Bethesda III nodules and 94%, 82%, 65%, and 98% for Bethesda IV nodules, respectively. The overall false-negative rate was 2%. The NPV of GSC in thyroid nodules with oncocytic predominance was 100% in Bethesda III nodules and 98% in Bethesda IV nodules. However, the PPV of oncocytic nodules was low (17% in Bethesda III nodules and 45% in Bethesda IV nodules). Only 22% of thyroid nodules with benign GSC results grew during surveillance.
Conclusion
GSC is a key tool for managing patients with indeterminate cytology, including the higher-risk Bethesda IV category. GSC-benign thyroid nodules can be observed similarly to thyroid nodules with benign cytology.
Publisher
Oxford University Press
Subject
/ Aged
/ Biopsy
/ Cytology
/ Female
/ Genomics
/ Humans
/ Male
/ Nodules
/ Surgery
/ Thyroid
/ Thyroid Neoplasms - diagnosis
/ Thyroid Neoplasms - genetics
